Envoy Medical faces Nasdaq delisting for failing MVLS requirement

Envoy Medical, Inc.

Nasdaq notified Envoy Medical on August 26, 2025 that it failed to regain compliance with the $35M MVLS requirement within a 180-day cure period.
Company requested a hearing on August 29, 2025, which stays trading suspension until the Panel issues a decision.
Envoy cites recent debt extinguishment as a pathway to regain compliance but offers no assurance of continued listing.
Trading would have been suspended September 4, 2025 without the hearing request.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.